Sean Kevlahan, PhD is the Senior Director of Cell and Gene Therapy at Bio-Techne. He is a product driven entrepreneur, specialist in cell biology, and domain leader in cell/gene therapy bioprocessing. Prior to his role at Bio-Techne, he was the CEO and co-founder of Quad Technologies, which was recently acquired by Bio-Techne. Dr. Kevlahan has received numerous awards including being one of the top-26 finalist in MassChallenge, CASIS grant award, and 2017 emerging technology finalist by Bioprocessing International. He is a lead inventor of many patents and authored numerous publications utilizing Bio-Techne’s core QuickGel™ technology. Dr. Kevlahan holds a B.S in biochemistry from Hofstra University and received his Ph.D. in chemical engineering from Northeastern University.